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Abstract: Nine compounds bearing pyridinyl (or piperidinyl, benzimidazolyl, benzotriazolyl) groups
bound to an azelayl moiety through an amide bond were synthesized. The structural analogy with
some histone deacetylase inhibitors inspired their syntheses, seeking new selective histone deacetylase
inhibitors (HDACi). The azelayl moiety recalls part of 9-hydroxystearic acid, a cellular lipid showing
antiproliferative activity toward cancer cells with HDAC as a molecular target. Azelayl derivatives
bound to a benzothiazolyl moiety further proved to be active as HDACi. The novel compounds
were tested on a panel of both normal and tumor cell lines. Non-specific induction of cytotoxicity
was observed in the normal cell line, while three of them induced a biological effect only on the
osteosarcoma (U2OS) cell line. One of them induced a change in nuclear shape and size. Cell-cycle
alterations are associated with post-transcriptional modification of both H2/H3 and H4 histones.
In line with recent studies, revealing unexpected HDAC7 function in osteoclasts, molecular docking
studies on the active molecules predicted their proneness to interact with HDAC7. By reducing side
effects associated with the action of the first-generation inhibitors, the herein reported compounds,
thus, sound promising as selective HDACi.
Keywords: cancer; pyridine; pyrimidine; 9-hydroxystearic acid; azelaic acid; osteosarcoma;
molecular docking
1. Introduction
Nitrogen-containing heterocycles are an important class of compounds of wide interest toward
many applied fields, such as material, agrochemical, and medicinal chemistry. One of the simplest
aza-heteroaromatics is pyridine (1, Figure 1), first isolated by Anderson in 1851 [1], which plays a key
role both in organic chemistry (as solvent and reactant) and in biological systems, since its nucleus
belongs to many coenzymes and vitamins.
Insertion of a further aza-moiety within the six-membered pyridine structure gives 1,2-diazines,
1,3-diazines, or 1,4-diazines, whose ancestors are pyridazine (2), pyrimidine (3), and pyrazine (4),
respectively (Figure 1).
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Figure 1. Structures of pyridine (1), pyridazine (2), pyrimidine (3), and pyrazine (4). 
Most of them are found in plants, animals, insects, marine organisms, and microorganisms. The 
effectiveness in the biological field lies in the key-core structure of nucleotides and coenzymes and in 
their role as pharmaceutical drugs, including anticancer agents. Some examples (Figure 2 ) are (i) 
imitanib, a tyrosine kinase inhibitor used in some kinds of chronic myelogenous leukemia (CML), 
acute lymphocytic leukemia (ALL), and gastrointestinal stromal tumors (GIST) [2,3]; (ii) 
mocetinostat, a histone deacetylase inhibitor for the treatment of a variety of cancers, including 
follicular lymphoma, Hodgkin’s lymphoma, and acute myelogenous leukemia [4]; (iii) berzosertib 
(VE-822), an ATR kinase inhibitor, which proved to be effective in vivo in the treatment of non-small-
cell lung and pancreatic cancer [5,6]. 
 
Figure 2. Structures of imatinib, mocetinostat, and berzosertib. 
Pentatomic-aza-heteroaromatics bearing two different heteroatoms, such as thiazoles or 
imidazoles, together with their benzocondensated derivatives, are also found in many natural 
compounds and are of great importance as bioactive compounds [7,8]. For a long time, our interest 
focused on the synthesis and reactivity of thiazoles and benzothiazole derivatives [9–15]. Recently, 
we performed a SNAr reaction between 2-aminobenzothiazole derivatives and 7-chloro-4,6-
dinitrobenzofuroxan, and we exploited the action of the products toward the natural strain in Vibrio 
genus and different bacterial lux-biosensors [16]. Furthermore, we explored the activity shown by the 
azelayl scaffold connected to the 2-aminobenzothiazolyl moiety, disclosing that some of the 
synthesized hybrid systems behave as histone deacetylase inhibitors (HDACi) [17]. The choice to 
bind the benzothiazolyl group to the –(CH2)7COOMe chain through an amide bond was inspired by 
the following circumstances: (i) the above reported carbon chain constitutes a moiety of the 
endogenous cellular lipid 9-hydroxystearic acid (9-HSA) [18], with antiproliferative activity against 
cancer cells, including human colon cancer [19–21] and osteosarcoma [22,23]; (ii) 9-HSA, as well as 
the methyl ester [24], acts as a histone deacetylase inhibitor (HDACi) [25–27]; (iii) the structure of the 
designed compounds is analogous to the well-known vorinostat molecule [28], where a methyl ester 
replaced a hydroxamic acid group. Based on the above considerations, we planned to synthesize 
similar novel derivatives with an azelayl scaffold bound through an amide bond to pyridine, 1,3-
diazine, benzimidazol, and benzotriazol moieties. All the novel compounds were tested on five cell 
lines. For the compounds that showed promising half maximal inhibitory concentration (IC50) values, 
further experiments and in silico studies were run to predict whether the molecular target might be 
HDACi, as in the case of benzothiazolyl derivatives. Herein, we report the results obtained.  
Figure 1. Structures of pyridine (1), pyridazine (2), pyri idine (3), and pyrazine (4).
Most of them are found in plants, animals, insects, marine organisms, and microorganisms.
The effectiveness in the biological field lies in the key-core structure of nucleotides and coenzymes
and in their role as pharmaceutical drugs, including anticancer agents. Some examples (Figure 2) are
(i) imitanib, a tyrosine kinase inhibitor used in some kinds of chronic myelogenous leukemia (CML),
acute lymphocytic leukemia (ALL), and gastrointestinal stromal tumors (GIST) [2,3]; (ii) mocetinostat,
a histone deacetylase inhibitor for the treatment of a variety of cancers, including follicular lymphoma,
Hodgkin’s lymphoma, and acute myelogenous leukemia [4]; (iii) berzosertib (VE-822), an ATR kinase
inhibitor, which proved to be effective in vivo in the treatment of non-small-cell lung and pancreatic
cancer [5,6].
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Pentatomic-aza-heteroaromatics bearing two different heteroatoms, such as thiazoles or imidazoles,
together with their benzocondensated derivatives, are also found in many natural compounds and
are of great importance as bioactive compounds [7,8]. For a long time, our interest focused on the
synthesis and reactivity of thiazoles and benzothiazole derivatives [9–15]. Recently, we performed a
SNAr reaction between 2-aminobenzothiazole derivatives and 7-chloro-4,6-dinitrobenzofuroxan, and
we exploited the action of the products toward the natural strain in Vibrio genus and different bacterial
lux-biosensors [16]. Furthermore, we explored the activity shown by the azelayl scaffold connected to
the 2-aminobenzothiazolyl moiety, disclosing that some of the synthesized hybrid systems behave
as histone deacetylase inhibitors (HDACi) [17]. The choice to bind the benzothiazolyl group to the
–(CH2)7COOMe chain through an amide bond was inspired by the following circumstances: (i) the
above reported carbon chain constitutes a moiety of the endogenous cellular lipid 9-hydroxystearic acid
(9-HSA) [18], with antiproliferative activity against cancer cells, including human colon cancer [19–21]
and osteosarcoma [22,23]; (ii) 9-HSA, as well as the methyl ester [24], acts as a histone deacetylase
inhibitor (HDACi) [25–27]; (iii) the structure of the designed compounds is analogous to the well-known
vorinostat molecule [28], where a methyl ester replaced a hydroxamic acid group. Based on the above
considerations, we planned to synthesize similar novel derivatives with an azelayl scaffold bound
through an amide bond to pyridine, 1,3-diazine, benzimidazol, and benzotriazol moieties. All the
novel compounds were tested on five cell lines. For the compounds that showed promising half
maximal inhibitory concentration (IC50) values, further experiments and in silico studies were run to
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predict whether the molecular target might be HDACi, as in the case of benzothiazolyl derivatives.
Herein, we report the results obtained.
2. Results and Discussion
2.1. Chemistry
The two series of novel heterocyclic derivatives 4a–c and 5a–c were synthesized through a
Schotten Bauman type reaction (Scheme 1), by reacting acyl chloride of the mono methyl azelate
(1, synthesized from oxalyl chloride and mono methyl ester of azelaic acid) and aminopyridines 2a–c
or aminopyrimidines 3a–c (Scheme 1).
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To the best of our knowledge, such a reaction is not reported in the literature so far. This might be
due to the stronger basicity of the amino group of the 2-aminopyrimidine (3a) with respect to that of the
other isomers, as supported by comparing the pKa values of 3a and 3c (20.5 and 18.4, respectively) [29].
Adopting the same strategy, the by-reactions between 1 and benzimidazole (7a) or benzotriazole
(7b) afford the azelaic derivatives 8a and 8b, respectively (Scheme 3).
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All the above compounds underwent biological tests to assess their activity toward four cancer
cells lines, U2OS (human osteosarcoma), HT29 (human colon adenocarcinoma), PC3 (human prostatic
carcinoma), and IGROV1 (human ovarian carcinoma), as well as a normal human adult fibroblast cell
line (see Section 2.2).
2.2. Biological Activity
2.2.1. In Vitro Effects on Cell Viability
Cell lines included in the evaluation of toxicity profiles were malignant U2OS, HT29, PC3, and
IGROV1, and a normal human adult fibroblast cell line HDFa. IC50 values of the drugs were calculated
using Prism, fitted by means of sigmoidal fit and listed in Table 1.
Table 1. Half maximal inhibitory concentration (IC50) of compounds in different cell lines after 48 h of
treatment (µM). (n.a. = non active; DMSO = dimethyl sulfoxide).
Compound Solvent U2OS IC50(µM)
HDFa IC50
(µM)
HT29 IC50
(µM)
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(µM)
IGROV1
IC50 (µM)
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IC50 analysis showed that all compounds had no effect on the normal cell line. Among tumor cell
lines, only U2OS was sensitive to some compounds, such as 5a, 6, and 8a.
The chemotherapeutic drugs used in the treatment of osteosarcoma belong to two different classes:
the DNA intercalating agents and the histone deacetylase inhibitors. Cisplatin, doxorubicin, and
5-fluorouracile show an IC50 of 1.67 µM, 0.5 µM, and 0.3 µM, respectively, in the U2OS cell line [30,31].
These effective and powerful compounds are associated with two important problems: (1) their mode
of action is linked to their ability to crosslink with the purine bases on the DNA, thereby interfering
with DNA repair mechanisms, causing DNA damage, and subsequently inducing death in cancer and
normal cells; (2) they frequently induce multidrug resistance.
Some studies demonstrated that HDACIs, such as SAHA (SuberAniloHydroxamic Acid), sodium
butyrate, and trichostatin A (TSA), are able to inhibit human osteosarcoma growth at different IC50
values of 5 µM, 5 µM, and 0.5 µM, respectively [32,33]. Our compounds show higher IC50, but they
offer the important advantage of not inducing cytotoxic effects in normal cells.
2.2.2. Effects on Cell Proliferation
To gain some insight into the biological effects of these novel derivatives, the most active
compounds on U2OS cell lines, 5a, 6, and 8a were subjected to additional studies. To infer whether
their effects were due to interference with cell-cycle progression, DNA profiles of cultured cells were
examined by flow cytometry. While compound 5a and 8a caused a slight accumulation in the synthesis
(S) phase, compound 6 induced an increase in the gap 0/gap 1 (G0/G1) fraction, with concomitant
decrease in the G2/mitosis (M) phase. Interestingly, compound 6 enlarged cell nucleus size, as shown
in Figure 3, where the propidium iodide (PI) fluorescence, indicating the amount of DNA per cell, is
plotted against the forward scatter (FS) signal, which is proportional to the size of the analyzed particle.
Again, the mean channel of FS distribution was very similar for control cells, 5a, and 8a treated samples
(730, 735, and 780, respectively), while sample 6 showed a mean channel of the FS distribution of 905.
As clear from Figure 3, the nuclei in all cell-cycle phases were affected.
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Figure 3. Flow cytometric assays of U2OS cells treated with compounds 5a, 6, and 8a, at the
concentrations reported. In the upper row, the DNA distribution of a typical experiment in control and
treated cells; the lower row indicates the biparametric cytograms of the DNA distribution (FL2) versus
forward scatter (FAL signal. The compounds analyzed are reported between the two rows.
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Nuclear size and shape are currently not only considered connected to the changes in DNA
content and structure during cell-cycle progression, but it is also well known that alteration of nuclear
morphology could be due to differentiation [34], pathologies as cancer [35,36], or to senescence [37].
Nuclear size could also be affected by drugs, such as intercalating drugs [37] or etoposide [38].
Interestingly, the fatty palmitic acid increases nuclear size in chick embryonic cardiomyocytes [39],
as well as in mouse fibroblasts [40]. The mechanism of these effects is not disclosed, even if it was
hypothesized that the lipid, or its metabolites, could interact with DNA, thereby altering the structure
of the nucleus, or that they activate cellular metabolism, thereby increasing protein synthesis [39].
2.2.3. Effect on Histone Acetylation
To identify acetylated histones, we analyzed the nuclear cell lysates by Western blot using a
15% polyacrylamide gel electrophoresis. After electrophoresis, the proteins were transferred to a
nitrocellulose membrane and then immunoblotted with an anti-acetyl lysine monoclonal antibody.
As shown in Figure 4, the antibody could detect the accumulation of acetylated proteins induced
in U2OS cells by treatment with compounds 6, 5a, and 8a. Differences in the density of bands are
thought to reflect differences in protein acetylation levels. Histone acetylation signals were quantified
by densitometry and normalized on histone H1. Histones H2/H3 acetylation increased by 28%
upon treatment with 6 for 6 h with no effect on H4 acetylation, whereas compound 8a induced
hyperacetylation by 30% on histone H4 only. Interestingly, compound 5a caused a post-transcriptional
modification of both H2/H3 and H4 histones, increasing acetylation by 89% and 22%, respectively.
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33,342. Representative images are shown (scale bar = 20 μm). (B) Image densitometry measured using 
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2.3. Docking Evaluation 
To verify the biochemical data observed for 5a, 6, and 8a species and to explore the binding 
mode and the potential affinity toward the catalytic Zn2+ active site of some HDACs, the synthesized 
Figure 4. Effect of compounds 5a, 6, and 8a on histone acetylation levels. (A) Cell nuclear extracts were
prepared and subjected to Western blot analysis for acetylated (Ac) histones H2/H3 and H4. Histone H1
was used as lo ding control. A repr entative experiment is shown, which was repeated three times.
(B) Densitometric analysis of the ba ds (mean ± SD; = 3) is shown. * p ≤ 0.05, *** p ≤ 0.01 vs. control.
These effects induced by the above compounds on histone acetylation are not associated with
events involved in apoptotic death. The analysis of the nucleus labeling with Hoechst 33,342 shows
indeed no morphological alterations typical of apoptotic cell death (Figure 5). However, the compounds
induced a state of nuclear alteration, as shown in Figure 5, where it is possible to see how the compounds
5a and 8a caused a dim staining of nuclei, while compound 6 induced an increase in nuclear size,
as observed by the flow cytometric assay.
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2.3. Docking Evaluation
To verify the biochemical data observed for 5a, 6, and 8a species and to explore the binding
mode and the potential affinity toward the catalytic Zn2+ active site of some HDACs, the synthesized
inhibitors were docked to the following structures involved in the histone deacetylation pathway:
(i) HDAC1, HDAC2, HDAC3, and HDAC8, belonging to the class I HDACs; (ii) HDAC4 and HDAC7,
belonging to the class II HDACs.
The target macromolecules were selected by analyzing the action modes of some antitumor drugs
pertaining to the category of HDACs. Recent studies revealed an unexpected function for HDAC7
in osteoclasts different from the function of HDAC3. Suppression of HDAC7 enhances osteoclast
formation, whereas overexpression of HDAC7 impairs osteoclast formation, indicating that HDAC7
represses osteoclast differentiation [41]. Moreover, HDAC7 was found to be overexpressed in pancreatic
cancer and acute lymphoblastic leukemia and was reported as insensitive to its previously designated
HDACi, trichostatin A (TSA) [42,43].
Our benzimidazolyl (8a) and pyrimidinyl (5a,6) derivatives were found to have the minimum
requirements for tight binding at the pocket Zn2+ active site of the HDAC domain whether in class I
or II examined macromolecules. In the literature, compounds similar to the studies herein showed
evidence for Zn complex formation [44], and the selected target proteins for docking evaluation of
the proposed compounds were retrieved from the Protein Data Bank (PDB; http:/www.rcsb.org/pdb/)
and were as follows: HDAC1 (PDB: 5ICN), HDAC2 (PDB: 4LXZ), HDAC3 (PDB: 4A69, HDAC8
(PDB: 4QA3), HDAC4 (PDB: 2VQM), and HDAC7 (PDB: 3C0Z). Binding modes and binding affinities
of the evaluated compounds within the catalytic Zn2+ pocket site of all the selected HDACs were
calculated using the Autogrid 4.0 and Autodock 4.2 programs [45]. The ADT 1.6.1 package was used
for visualizing the results (for the preparation of the molecules and the target macromolecules, and for
the procedure of molecular docking, see Section 3).
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Analysis of the Binding Mode
The binding pose of the evaluated compounds and their interactions in the active binding site of the
selected HDACs were analyzed. The predicted binding free energy (BE, which includes intermolecular
energy and torsional free energy) was used as a ranking criterion. The conformation with the lowest
ranking docked binding energy (BE) was considered as the “best” docking result.
Satisfactory docking results with good affinity results were observed for the three compounds
(5a, 6, and 8a) whether for the evaluated class I or class II HDACs, as well as virtual constants of
inhibition (Ki) at micromolar concentration. The compounds docked and perfectly fitted into the active
pocket site of the examined HDAC2, HDAC8, and HDAC7, as indicated from binding free energy
reported in Table 2 and from analysis of the ligand binding pose inside the active binding sites.
Table 2. Docking results, expressed in term of binding free energy (∆G, kcal/mol) and calculated
inhibition constant (Ki, nM or µM).
HDAC Class I HDAC Class II
HDAC1-5ICN HDAC2-4LXZ HDAC3-4A69 HDAC8-4QA3 HDAC4-2VQM HDAC7-3C0Z
BE_∆G
(mol_5a) −5.80 −6.90 −5.47 −8.05 −6.03 −7.26
∆G (mol_6) −6.36 −7.24 −5.92 −8.14 −7.61 −7.00
∆G (mol_8a) −6.83 −7.73 −6.38 −8.63 −6.70 −7.61
Ki (mol_5a) 55.93 µM 8.77 µM 98.23 µM 1.26 µM 37.85 µM 4.78 µM
Ki (mol_6) 21.78 µM 4.94 µM 45.52 µM 1.07 µM 2.62 µM 7.37 µM
Ki (mol_8a) 9.92 µM 2.17 µM 21.08 µM 472.15 nM 12.29 µM 2.62 µM
BE_∆G: binding energy (kcal/mol); Ki: calculated inhibition constant.
Along the evaluated compounds, the best docking results were observed for the class I HDAC8
and class II HDAC7; the best poses of compounds 5a, 6, and 8a into the active binding site had an
estimated binding free energy (∆G) of −8.05, −8.14, and −8.63 kcal/mol, respectively (for HDAC8),
and −7.26, −7.00, and −7.61 kcal/mol, respectively (for HDAC7). The best calculated corresponding
inhibition constants (Ki) related to HDAC8 were found to be 1.26 µM, 1.07 µM, and 472.15 nM,
respectively, for 5a, 6, and 8a compounds, while they were 4.78 µM, 7.37 µM, and 2.62 µM, for the same
compounds in the case of HDAC7. Similar results for ∆G of −7.24 and −7.73 kcal/mol were observed
with HDAC2 for compounds 6 and 8a with the corresponding best calculated inhibition constants (Ki)
equal to 4.94 µM and 2.17 µM, respectively. Compound 6 also showed similarly good results with the
other examined HDAC4 (∆G of −7.61 kcal/mol and inhibition constant (Ki) equal to 2.62 µM).
The structures of HDAC enzymes are characterized by the active Zn2+ ion at the pocket bottom,
the hydrophobic channel reaching the active Zn2+ ion, and the surface rim at the entrance of the pocket.
Thus, to assess the precise binding pose of the synthesized compounds in the binding pocket of HDAC1
(PDB code: 5ICN), HDAC2 (PDB code 4LXZ), HDAC3 (PDB code 4A69), HDAC8 (PDB code 4QA3),
HDAC4 (PDB code 2VQM), and HDAC7 (PDB code: 3C0Z), we performed a molecular docking study.
This docking study acknowledged the inhibitory potential of 5a, 6, and 8a against both HDAC8
and HDAC7 isoforms.
The docking results showed that these inhibitors are able to coordinate to the zinc ion. The in silico
docking study displayed different poses of synthesized compounds for HDAC8 and HDAC7 isoforms.
All the compounds (5a, 6, and 8a) are characterized by one (5a and 8a) or two (6) terminal methyl
ester groups at the end of the long aliphatic chain, connected to the heterocyclic moiety by an amide
bond, and they exhibit slightly better values of binding free energies to class I HDAC8, (Table 2).
For the sake of clarity, in Figure 6, we report only the docking pose of the molecule 8a (showing
the best Ki inhibition) in the binding site of HDAC8 and HDAC7, belonging to class I and II HDACs.
In the Supplementary Materials, the figures related to the following docking poses are reported: for
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molecule 8a in HDAC2 (Figure S28), for molecules 5a and 6 in the binding site of HDAC8, HADC7,
and HDAC2 (Figures S29 and S30, respectively), and for all the evaluated compounds in the HDAC8
and HDAC7 active binding sites (Figure S31).
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perfectly into the active pocket in HDAC8 differently from the HDAC7 isoform, while the orientation 
of compound 6 showed a terminal ester group of one lateral chain into the pocket. The docking pose 
of 5a, 6, and 8a with HDAC8 indicated that the oxygen atom of the amide group of all compounds 
formed a potential hydrogen bonding interaction with the NH+ of His180 at the rim of the pocket. 
On the other hand, the pose of all the compounds to HDAC7 indicated that the oxygen atom of 
the amide group formed a potential hydrogen bonding interaction with the NH+ of His709 at the rim 
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Figure 7 reports hydrogen bond and chelation interactions in the active site of complexes 
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indicated without a dashed line. 
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Figure 7. Hydrogen bond and chelation interactions in the active site of (a) complex 8a–HDAC8-
4QA3, and (b) complex 8a–HDAC7-3C0Z. Amino-acid residues within 5 Å are indicated without a 
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str ct r ( r t i ata Bank identifier (PDB ID): 4QA3) and (b) HDAC7 structure (PDB ID: 3C0Z).
In both pictures, the zinc ion is represented as a green sphere.
The terminal ester group of compound 8a and of one lateral chain of 6 were accommodated into
the active pocket found in the HDAC7 isoform, while 5a had the pyrimidine group inserted in the
bottom of the pocket. The benzimidazole moiety of 8a and the pyrimidinyl group of compound 5a fit
perfectly into the active pocket in HDAC8 differently from the HDAC7 isoform, while the orientation
of compound 6 showed a terminal ester group of one lateral chain into the pocket. The docking pose
of 5a, 6, and 8a with HDAC8 indicated that the oxygen atom of the amide group of all compounds
formed a potential hydrogen bonding interaction with the NH+ of His180 at the rim of the pocket.
On the other hand, the pose of all the compounds to HDAC7 indicated that the oxygen atom of
the amide group formed a potential hydrogen bonding interaction with the NH+ of His709 at the rim
of the pocket. A comprehensive overview is reported in the Supplementary Materials (Figure S31).
Figure 7 reports hydrogen bond and chelation interactions in the active site of complexes between
8a and HDAC8-4QA3 (a) and 8a with HDAC7-3C0Z (b); amino-acid residues within 5 Å are indicated
without a dashed line.
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As can be seen, the coordination sphere of the zinc ion involved, in both reported cases in Figure 7,
interactions with the oxygen atom of amide group of compound 8a and two histidine residues (one of
them also involved in a hydrogen bond with the oxygen atom of the amide group, and two aspartic
acid residues).
Tables S1–S3 (Supplementary Materials) report the “virtual” interactions of all compounds
docked with amino-acid residues and the zinc ion in the active site of HDAC8-4QA3, HDAC7-3C0Z,
and HDAC2-4LXZ.
3. Materials and Methods
3.1. Chemical Syntheses
The reagents used, unless stated otherwise, were purchased from Sigma-Aldrich (Milan, Italy).
CH2Cl2 was anhydrified by distillation over P2O5. Chromatographic purifications (FC) were carried
out on glass columns packed with silica gel (Merck grade 9385, 230–400 mesh particle size, 60 Å pore
size) at medium pressure. Thin-layer chromatography (TLC) was performed on silica gel 60 F254-coated
aluminum foils (Fluka, Buchs, Switzerland). The spots related to 9-methoxy-9-oxononanoic acid were
revealed using a bromocresol green solution (6% in ethanol).
The nuclear magnetic resonance spectra were recorded at 25 ◦C on Varian spectrometers Mercury
400 or Inova 600 (Varian, Palo Alto, CA, USA) operating at 400 or 600 MHz (for 1H-NMR) and
100.56 or 150.80 MHz (for 13C-NMR), respectively. Signal multiplicities were established by DEPT-135
experiments. Chemical shifts were measured in δ (ppm) with reference to the solvent (δ= 7.26 ppm
and 77.00 ppm for CDCl3, for 1H- and 13C-NMR, respectively). J-values are given in Hz. Electrospray
ionization (ESI)-MS and ESI high-resolution (HR)MS spectra were recorded using a Waters ZQ 4000
and Xevo instrument, respectively. Melting points (m.p.) were measured on a Büchi 535 apparatus
(Flawil, Zwitzerland) and are uncorrected.
3.1.1. Synthesis of Methyl 9-Chloro-9-oxononanoate (1)
9-Methoxy-9-oxononanoic acid (1.12 mL, 5.87 mmol) was introduced in a dried three-necked
round-bottom flask (equipped with a dropping funnel and kept under nitrogen atmosphere) and
dissolved in 45 mL of anhydrous CH2Cl2. Oxalyl chloride (0.53 mL, 6.26 mmol), diluted in 5 mL of
anhydrous CH2Cl2, was introduced in the funnel and added dropwise to the magnetically stirred
solution over 10 min. The reaction was monitored through 1H-NMR spectroscopy. When the signals of
the starting acid disappeared, the solvent was removed under reduced pressure, with care to avoid
contact with moisture, and the residue was dissolved in anhydrous CH2Cl2, in an amount calculated
in order to obtain a 0.5 M solution of acyl chloride. The chemical–physical data of compound 1 agreed
with those reported in the literature [18].
3.1.2. General Procedure for the Synthesis of Compounds 4a–c, 5a–c, 6, and 8a,b
In a dried apparatus and under nitrogen atmosphere, 1.0 mL of a 0.5 M solution of 1 in CH2Cl2
(0.0005 mol) was added to a magnetically stirred solution containing 0.001 mol of the selected
heterocyclic compound 2a–c (or 3a–c, or 7a,b) dissolved in 5 mL of anhydrous CH2Cl2. The reaction
course was monitored by 1H-NMR spectroscopy until the acyl chloride signals disappeared. Then, water
(10 mL) was added, and the mixture was extracted with dichloromethane (3 × 10 mL). The organic layer
was dried over anhydrous MgSO4 and filtered. After removal of the solvent under reduced pressure,
the products were purified by column chromatography on silica gel or by bulb-to-bulb distillation.
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Methyl 9-oxo-9-(pyridin-2-ylamino)nonanoate (4a), purified by FC (ethyl acetate/dichloromethane
40/60). White solid; 0.054 g (39%); m.p. 59–60 ◦C; 1H-NMR (600 MHz, CDCl3), δ (ppm): 8.43 (br. s,
1H, NH), 8.25 (d, J = 5.2 Hz, 1 H, CH), 8.21 (d, J = 8.3 Hz, 1 H, CH), 7.69 (dt, J1 = 7.2 Hz, J2 = 1.7 Hz,
1H, CH), 7.02 (dd, J1 = 7.1 Hz, J2 = 5.1 Hz, 1 H, CH), 3.65 (s, 3 H, COOCH3), 2.37 (t, J = 7.6 Hz, 2 H,
CH2CON), 2.28 (t, J = 7.6 Hz, 2 H, CH2COOCH3), 1.71 (quint., J = 7.5 Hz, 2 H, CH2CH2CON), 1.60
(quint, J = 7.1 Hz, 2 H, CH2CH2COOCH3), 1.39–1.27 (m, 6 H, CH2); 13C-NMR (150 MHz, CDCl3)
δ (ppm): 174.2 (C), 171.8 (C), 151.5 (C), 147.6 (CH), 138.4 (CH), 119.6 (CH), 114.1 (CH), 51.4 (CH3),
37.6 (CH2), 34.0 (CH2), 28.94 (CH2), 28.9 (CH2), 28.8 (CH2), 25.2 (CH2), 24.8 (CH2); ESI-MS− (m/z):
313 [M + Cl]−; ESI-HRMS: calculated for C15H22N2NaO3+: 301.1523, found: 301.1528
Methyl 9-oxo-9-(pyridin-3-ylamino)nonanoate (4b), purified by FC (ethyl acetate/dichloromethane
40/60). White solid; 0.076 g (55%); m.p. 75.5–77.7 ◦C; 1H-NMR (600 MHz, CDCl3) δ (ppm) 8.80 (br.s,
1 H, NH); 8.58 (d, J = 2.3 Hz, 1 H, CH); 8.26 (d, J = 4.5 Hz, 1 H, CH); 8.20 (d, J = 8.1 Hz, 1 H, CH); 7.23
(dd, J1 = 8.2 Hz, J2 = 4.6 Hz, 1 H, CH); 3.63 (s, 3 H, COOCH3); 2.35 (t, J = 7.8 Hz, 2 H, CH2CON); 2.26
(t, J = 7.8 Hz, 2 H, CH2COOCH3); 1.67 (quint., J = 7.3 Hz, 2 H, CH2CH2CON); 1.56 (quint., J = 7.3 Hz,
2 H, CH2CH2COOCH3); 1.34–1.23 (m, 6 H, CH2);13C-NMR (150 MHz, CDCl3) δ (ppm): 174.4 (C), 172.4
(C), 144.3 (CH), 140.7 (CH), 135.5 (C), 127.4 (CH), 123.8 (CH), 51.4 (CH3), 37.2 (CH2), 33.9 (CH2), 28.8
(CH2), 28.76 (CH2), 28.72 (CH2), 25.2 (CH2), 24.7 (CH2); ESI-MS+ (m/z): 279 [M + H]+, 301 [M + Na]+;
ESI-HRMS: calculated for C15H22N2NaO3+: 301.1523, found: 301.1528.
Methyl 9-oxo-9-(pyridin-4-ylamino)nonanoate (4c), purified by FC (methanol/ethyl acetate 5/95).
White solid; 0.059 g (42%); m.p. 83–85 ◦C; 1H-NMR (600 MHz, CDCl3) δ (ppm): 8.91 (s, 1 H, NH), 8.43
(d, J = 5.1 Hz, 2 H, CH), 7.56 (d, J = 5.1 Hz, 2 H, CH), 3.64 (s, 3 H, COOCH3), 2.35 (t, J = 7.6 Hz, 2 H,
CH2CON), 2.28 (t, J = 7.6 Hz, 2 H, CH2COOCH3), 1.67 (quint., J = 7.4 Hz, 2 H, CH2CH2CON), 1.57
(quint., J = 7.4 Hz, 2 H, CH2CH2COOCH3), 1.35–1.25 (m, 6 H, CH2); 13C-NMR (150 MHz, CDCl3) δ
(ppm): 174.4 (C), 172.7 (C), 149.9 (CH), 146.0 (C), 113.7 (CH), 51.5 (CH3), 37.5 (CH2), 33.9 (CH2), 28.8
(CH2), 28.77 (CH2), 28.73 (CH2), 25.1 (CH2), 24.7 (CH2); ESI-MS− (m/z): 277 [M − H]−, 313 [M + Cl]−;
ESI-HRMS: calculated for C15H22N2NaO3+: 301.1523, found: 301.1528.
Methyl 9-oxo-9-(pyrimidin-2-ylamino)nonanoate (5a), purified by FC (methanol/ethyl acetate 5/95).
White solid; yield 0.067 g (32%); m.p. 86.2–87.3 ◦C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 9.55 (br.s, 1 H,
NH), 8.61 (d, J = 4.9 Hz, 2 H, CH), 6.97 (7, J = 4.9 Hz, 1 H, CH) 3.62 (s, 3 H, COOCH3), 2.73 (t, J = 7.4 Hz,
2 H, CH2CON), 2.26 (t, J = 7.6 Hz, 2 H, CH2COOCH3), 1.70 (quint., J = 7.3 Hz, 2 H, CH2CH2CON),
1.59 (quint., J = 7.0 Hz, 2 H, CH2CH2COOCH3), 1.45–1.2 (m, 6H, CH2); 13C-NMR (100 MHz, CDCl3)
δ (ppm): 174.2 (C), 173.7 (C), 158.2 (CH), 157.6 (C), 115.9 (CH), 51.3 (CH3), 37.3 (CH2), 33.9 (CH2), 28.93
(CH2), 28.90 (CH2), 28.8 (CH2), 24.8 (CH2) (one signal overlapped); ESI-MS+ (m/z): 280 [M + H]+,
302 [M + Na]+, 318 [M + K]+; ESI-HRMS: calculated for C14H22N3NaO3+: 302.1475, found: 302.1481.
Methyl 9-oxo-9-(pyrimidin-4-ylamino)nonanoate (5b), purified by FC (methanol/ethyl acetate 5/95).
White solid; 0.056 g (40%); m.p. 92.0–94.2 ◦C; 1H-NMR (600 MHz, CDCl3) δ (ppm): 8.84 (s, 1 H, CH),
8.62 (d, J = 5.7 Hz, 1 H, CH), 8.18 (dd, J1 = 5.9 Hz, J2 = 1.2 Hz, 1 H, CH), 8.13 (br.s, 1 H, NH), 3.66 (s, 3 H,
COOCH3), 2.42 (t, J = 7.5 Hz, 2 H, CH2CON), 2.30 (t, J = 7.2 Hz, 2 H, CH2COOCH3), 1.72 (quint.,
J = 7.2 Hz, 2 H, CH2CH2CON), 1.62 (quint., J = 7.1 Hz, 2 H, CH2CH2COOCH3), 1.42–1.24 (m, 6 H,
CH2); 13C-NMR (150 MHz, CDCl3) δ (ppm): 174.2 (C), 172.5 (C), 158.4 (CH), 158.2 (CH), 156.9 (C), 110.2
(CH), 51.5 (CH3), 37.7 (CH2), 34.0 (CH2), 28.9 (CH2), 28.8 (CH2), 24.9 (CH2), 24.8 (CH2) (one signal
overlapped); ESI-MS+ (m/z): 280 [M + H]+, 302 [M + Na]+, 318 [M + K]+; ESI-HRMS: calculated for
C14H22N3NaO3+: 302.1475, found: 302.1481.
Methyl 9-oxo-9-(pyrimidin-5-ylamino)nonanoate (5c), purified by FC (methanol/ethyl acetate 5/95).
Orange solid; 0.036 g (26%); m.p. 78.6–80.2 ◦C; 1H-NMR (300 MHz, CDCl3) δ (ppm) 9.29 (s, 2 H, CH),
8.98 (s, 1 H, CH); 8.63 (br. s, 1 H, NH), 3.66 (s, 3 H, COOCH3), 2.47 (t, J = 7.6 Hz, 2 H, CH2CON), 2.31
(t, J = 7.3 Hz, 2 H, CH2COOCH3), 1.74 (quint., J = 7.4 Hz, 2 H, CH2CH2CON), 1.62 (quint., J = 7.4 Hz,
2H, CH2CH2COOCH3), 1.42–1.28 (m, 6 H, CH2); 13C-NMR (150 MHz, CDCl3) δ (ppm): 174.4 (C),
172.5 (C), 150.7 (CH), 147.2 (CH), 134.8 (C), 51.5 (CH3), 37.1 (CH2), 34.0 (CH2), 28.7 (CH2), 25.0 (CH2),
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24.7 (CH2) (two signals overlapped); ESI-MS+ (m/z): 280 [M + H+]+, 302 [M + Na+]+, 318 [M + K+]+;
ESI-HRMS: calculated for C14H22N3NaO3+: 302.1475, found: 302.1481.
Dimethyl 9,9’-(pyrimidin-2-ylazanediyl)bis(9-oxononanoate) (6), purified by FC (methanol/ethyl acetate
5/95). Colorless liquid; 0.016 g (14%); 1H-NMR (600 MHz, CDCl3) δ (ppm): 8.81 (d, J = 4.7 Hz, 2 H,
CH), 7.33 (t, J = 4.8 Hz, 1 H, CH), 3.59 (s, 6 H, COOCH3), 2.47 (t, J = 7.4 Hz, 4 H, CH2CON), 2.22
(t, J = 7.6 Hz, 4 H, CH2COOCH3), 1.60–1.48 (m, 8 H, CH2CH2COOCH3), 1.29–1.18 (m, 12 H, CH2),
13C-NMR (150 MHz, CDCl3) δ (ppm): 175.0 (C), 174.0 (C), 159.5 (C), 159.3 (CH), 120.3 (CH), 51.2 (CH3),
37.9 (CH2), 33.8 (CH2), 28.75 (CH2), 28.70 (CH2), 28.66 (CH2), 28.60 (CH2), 24.6 (CH2), 24.0 (CH2);
ESI-MS− (m/z): 498 [M + Cl]−; ESI-HRMS: calculated for C24H37N3NaO6+: 486.2575, found: 486.2580.
Methyl 9-(1H-benzo[d]imidazol-1-yl)-9-oxononanoate (8a), purified by bulb-to-bulb distillation at
150 ◦C and 0.1 mmHg. White solid; 0.075 g (50%); m.p. 83.0–84.3 ◦C; 1H-NMR (600 MHz, CDCl3) δ
(ppm): 8.40 (s, 1 H, CH), 8.25 (d, J = 7.9 Hz, 1 H, CH), 7.80 (d, J = 7.0 Hz, 1 H, CH), 7.43 (dt, J1 = 8.5 Hz,
J2 = 1.2 Hz, 1 H, CH), 7.40 (dt, J1 = 9.3 Hz, J2 = 1.6 Hz, 1 H, CH), 3.67 (s, 3 H, COOCH3), 3.00 (t, J = 7.4
Hz, 2 H, CH2CON), 2.32 (t, J = 7.3 Hz, 2H, CH2COOCH3), 1.88 (quint., J = 7.8 Hz, 2 H, CH2CH2CON),
1.64 (quint., J = 7.8 Hz, 2 H, CH2CH2COOCH3), 1.47 (quint., J = 7.7 Hz, 2H, CH2), 1.43–1.32 (m, 4 H,
CH2); 13C-NMR (150 MHz, CDCl3) δ (ppm): 174.2 (C), 170.3 (C), 143.9 (CH), 140.9 (C), 131.5 (C), 125.9
(CH), 125.0 (CH), 120.5 (CH), 115.6 (CH), 51.5 (CH3), 35.9 (CH2), 34.0 (CH2), 28.9 (CH2), 28.86 (CH2),
28.84 (CH2), 24.8 (CH2), 24.2 (CH2); ESI-MS+ (m/z): 303 [M + H+]+, 325 [M + Na+]+; ESI-HRMS:
calculated for C17H22N2NaO3+: 325.1523, Found: 325.1528
Methyl 9-(1H-benzo[d][1,2,3]triazol-1-yl)-9-oxononanoate (8b), purified by bulb-to-bulb distillation
at 150 ◦C and 0.1 mmHg. White solid; 0.032 g (20%); m.p: 55.5–57.2 ◦C; 1H-NMR (600 MHz, CDCl3)
δ (ppm): 8.28 (d, J = 8.3 Hz, 1 H, CH), 8.10 (d, J = 8.0 Hz, 1 H, CH), 7.64 (t, J = 7.8 Hz, 1 H,
CH), 7.49 (t, J = 7.8 Hz, 1 H, CH), 3.65 (s, 3 H, COOCH3), 3.40 (t, J = 7.4 Hz, 2 H, CH2CON), 2.30
(t, J = 7.6 Hz, 2 H, CH2COOCH3), 1.89 (quint., J = 7.8 Hz, 2 H, CH2CH2CON), 1.63 (quint., J = 7.5 Hz, 2
H, CH2CH2COOCH3), 1.48 (quint., J = 7.7 Hz, 2 H, CH2), 1.42–1.32 (m, 4 H, CH2); 13C-NMR (150 MHz,
CDCl3) δ (ppm) 174.1 (C), 172.5 (C), 146.1 (C), 131.1 (C), 130.3 (CH), 126.0 (CH), 120.1 (CH), 114.4
(CH), 51.4 (CH3), 35.4 (CH2), 34.0 (CH2), 28.9 (CH2), 28.8 (CH2), 24.8 (CH2), 24.3 (CH2) (one signal
overlapped); ESI-MS+ (m/z): 304 [M + H+]+, 326 [M + Na+]+.
3.2. Cell Culture and Treatments
3.2.1. Cell Culture
The human prostate cancer (PC3), human colon cancer (HT29), human bone osteosarcoma (U2OS),
and normal human adult fibroblast (HDFa) cell lines were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA), while the human ovarian cancer cell line (IGROV1) was
kindly provided by Istituto Nazionale Tumori (IRCCS, Milano, Italy). Cells were cultured in Roswell
Park Memorial Institute (RPMI)-1640 medium (Labtek Eurobio, Milan, Italy), supplemented with 10%
fetal calf serum (FCS; Euroclone, Milano, Italy) and 2mM l-glutamine (Sigma-Aldrich, Milano, Italy),
at 37 ◦C and 5% CO2 atmosphere. The compounds were dissolved in dimethyl sulfoxide (DMSO) in a
60 mM stock solution. In cell treatments, the final DMSO concentration never exceeded 0.1%.
3.2.2. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay
U2OS were seeded at 1.5 × 104 cells/well in a 96-well culture plastic plate (Orange Scientific,
Braine-l’Alleud, Belgium) and, after 24 h of growth, cells were exposed for additional 48 h
to increasing concentrations of compounds (0.1 µM and 500 µM) solubilized in RPMI-1640
medium. On the day of measurement, the culture medium was replaced with 0.1 mL of
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) dissolved in
phosphate-buffered saline (PBS) at the concentration of 0.2 mg/mL, and samples were incubated
for 2 h at 37 ◦C. To dissolve the blue-violet formazan salt crystals formed, 0.1 mL of isopropyl alcohol
was added to each well and incubated for 20 min. The absorbance at 570 nm was measured using a
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multiwell plate reader (Wallac Victor2, PerkinElmer, Milano, Italia), and viability was compared with
that of untreated cells, used as controls.
3.2.3. Cell Cycles
For the cell-cycle assay, U2OS cells were treated for 24 h with 35 µM of compound 6, 50 µM
of 5a, or 50 µM of 8a, detached with 0.11% trypsin (Sigma-Aldrich, S.Louis, MO, USA)/0.02%
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, S.Louis, MO, USA), washed in PBS, and
centrifuged. The pellet was resuspended in 0.01% Nonidet P-40 (Sigma-Aldrich, S.Louis, MO, USA),
10 µg/mL RNase (Sigma-Aldrich, S.Louis, MO), 0.1% sodium citrate, and 50 µg/mL propidium iodide
(PI) (Sigma-Aldrich, S.Louis, MO, USA), for 30 min at room temperature in the dark. PI fluorescence
and forward scatter (FS) signals were analyzed using a Beckman Coulter Epics XL-MCL flow cytometer.
DNA distribution in the cell cycle was analyzed by the MODFIT 5.0 software. As the signal collected
by a multichannel analyzer, the mean of the FS distribution is expressed as mean channel.
3.2.4. Histone Extraction, SDS-PAGE, and Western Blot
U2OS were cultured with 5a, 6, or 8a, for 6 h, and the histone fraction was immediately extracted.
Cells were harvested using 0.11% trypsin and 0.02% EDTA, washed twice with 10 mM sodium butyrate
(NaBu) in PBS, and nuclei were isolated according to Amellem et al. [46]. The nuclear pellet was
suspended in 0.1 mL of ice-cold water using a Vortex mixer, and concentrated H2SO4 was added to the
suspension to give a final concentration of 0.4 N. After incubation at 4 ◦C for 1 h, the suspension was
centrifuged for 5 min at 14,000× g, and the supernatant was taken and mixed with 1 mL of acetone.
After overnight incubation at −20 ◦C, the coagulate material was collected by microcentrifugation
and air-dried, and proteins were quantified using a protein assay kit (Bio-Rad, Hercules, CA, USA).
Histones were analyzed as previously described [24]. Briefly, histones were resolved by 15% SDS-PAGE
and immunoblotted with anti-acetylated lysine antibody (Cell Signaling Technology, Beverly, MA,
USA); the detection of immunoreactive bands was performed with a secondary antibody conjugated
with horseradish peroxidase and developed with an enhanced chemiluminescence (ECL) system,
developed with the enhanced chemiluminescence system Clarity Western (Bio-Rad, Hercules, CA,
USA), and quantification was done by Fluor-S Max MultiImager (Bio-Rad). Histone acetylation signals
were quantified by densitometry and normalized on histone H1.
3.2.5. Hoechst 33,342 Staining
Nuclear morphology was assayed using a specific dye Hoechst 33,342. U2OS treated cells were
washed, fixed, and then stained with 1 µM Hoechst 33,342 (Sigma-Aldrich, St Louis, MO, USA) for
15 min. Samples were embedded in Mowiol and analyzed using a Nikon C1s confocal laser-scanning
microscope, equipped with a Nikon PlanApo 40×, 1.4 numerical aperture (NA) oil immersion lens.
Images were quantified by ImageJ software (IMAJ 1.x).
3.3. Docking
Crystal structures of target HDACs, HDAC1 (PDB: 5ICN), HDAC2 (PDB: 4LXZ), HDAC3 (PDB:
4A69, HDAC8 (PDB: 4QA3), HDAC4 (PDB: 2VQM), and HDAC7 (PDB: 3C0Z), used for the docking
study, were obtained from the Protein Data Bank (http:/www.rcsb.org/pdb/). The target proteins were
prepared using Maestro 9.1 software (Schrödinger, LLC, New York, NY, USA 2010) deleting waters,
optimizing H-Bond assignments, and deleting original ligands. Before starting the docking calculations,
ligand geometry optimization was done using Gaussian 3 [47] by semi-empirical AM1 [48] in order to
obtain the minimum-energy conformation. The computational analysis was executed using AutoDock
4.2 [45] and Autogrid 4.0 on a Dual-Xeon T7400 Dell workstation. Grids (one grid for each atom type
in the ligand, plus an electrostatic and a desolvation map), were centered on the binding site and were
chosen to be large enough (60 × 60 × 60 Å) to allow the ligand to rotate freely, even in its most fully
extended conformation. Docking was performed using the AutoDock empirical free energy function
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and the Lamarckian genetic algorithm with local search. Lamarckian genetic algorithms can handle
ligands with more degrees of freedom than the simulated annealing method. In total, 150 docking runs
with 2,500,000 energy evaluations for each run were performed for each molecule and all the evaluated
HDACs. Cluster analysis (root-mean-square (RMS) tolerance equal to 0.5 Å) was then carried out
on the docked results. Inhibitors were compared according to the cluster with lowest docked energy
found. The inhibition constants (Ki) were calculated from the docked energy.
The same protocol was used as in previous studies [49].
4. Conclusions
A series of novel compounds bearing an aza-heterocyclic moiety bound to the azelayl scaffold by
an amide bond was synthesized to evaluate the biological effects induced on a panel of both normal and
tumor cell lines. Noteworthy, none of the compounds induced cytotoxicity in the normal fibroblast cell
line, while only osteosarcoma (U2OS) among the tumor cell lines appeared to be sensitive to compounds
such as 5a, 6, and 8a. The treatment with the compounds 5a and 8a induced an accumulation in the S
phase, while compound 6 caused an increase in the G0/G1 fraction with concomitant decrease in the
G2/M phase, and these changes in the cell cycle were associated with a post-transcriptional modification
of both H2/H3 and H4 histones. The above cited three active molecules underwent an in silico study
using histone deacetylases as the molecular target, revealing that they were able to interact with
HDAC 7. These findings are in line with the recent studies, which disclosed an unexpected function
for HDAC7 in osteoclasts, which is distinct from the function of HDAC3. Interestingly, compound 6
dramatically affected the FS signal of U2OS nuclei, indicating a change of the nuclei in both shape
and size. Overall, compounds 5a, 6, and 8a could be selective HDACi, achieving a greater clinical
utility by elimination or reduction of serious side effects, associated with the current non-selective
first-generation HDACi.
Supplementary Materials: The following are available online: Figures S1–S27: 1H- and 13C-NMR spectra of
compounds 4a–c, 5a–c, 6, 8a, 8b; Figure S28: docking pose for 8a in HDAC2; Figure S29: Docking pose for
molecule 5a in binding site of HDAC8, HADC7, and HDAC2; Figure S30: Docking pose for molecule 6 in binding
site of HDAC8, HADC7, and HDAC2; Figure S31: Docking pose for all the evaluated compounds in the HDAC8
and HDAC7 active binding sites.
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